All Pathways
CardiologyManagement

Post-MI Secondary Prevention (ESC 2023)

Post-MI Secondary Prevention (ESC 2023): Post-MI Patient → Antithrombotic Therapy → Beta-Blocker → SGLT2 Inhibitor → ICD Evaluation.

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Post-MI Patient

    After STEMI or NSTEMI

    1. Action

      Antithrombotic Therapy

      DAPT then maintenance

      • DAPT x 12 months
      • Aspirin + Ticagrelor/Prasugrel
      • Then aspirin indefinitely
      1. Action

        Beta-Blocker

        ≥1 year, indefinite if HF

        • Carvedilol, bisoprolol, metoprolol
        • Indefinite if LVEF ≤40%
        • Indefinite if arrhythmia/HF
        1. Action

          SGLT2 Inhibitor

          If HFrEF/HFmrEF/DM/CKD

          • Dapagliflozin or empagliflozin
          • Growing evidence post-MI
          1. Warning

            ICD Evaluation

            At ≥40 days post-MI

            • If LVEF ≤35% despite OMT x 3mo
            • Primary prevention SCD
            1. Outcome

              Lifelong Secondary Prevention

              Regular follow-up, optimize GDMT

          2. Action

            Cardiac Rehabilitation

            Class I recommendation

            • Exercise training
            • Risk factor education
            • Psychosocial support
    2. Action

      Lipid Therapy

      Aggressive LDL lowering

      • Target: LDL <55 mg/dL + ≥50% reduction
      • Recurrent event: <40 mg/dL
      • Step 1: High-intensity statin
      • Step 2: + Ezetimibe
      • Step 3: + PCSK9i
      1. Action

        ACEi/ARB/ARNI

        All post-STEMI patients

        • Especially if LVEF ≤40%
        • Anterior MI, HTN, DM
        • ARNI if HF develops
      2. Action

        MRA

        If LVEF ≤40% + symptoms/DM

        • Spironolactone or eplerenone
        • Monitor K+ and renal function

Guideline Source

ESC 2019 Dyslipidemia + ESC 2023 ACS Guidelines

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Drug dosing not included
  • Cardiac rehab details simplified
  • Does not address CABG-specific considerations

Contraindicated Populations

pediatric

Applicable Regions

EUUS

EU: ESC targets: LDL <55 mg/dL, <40 if recurrent

US: ACC/AHA similar but LDL targets may differ

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Post-MI Secondary Prevention (ESC 2023)?

The Post-MI Secondary Prevention (ESC 2023) is a management clinical algorithm for Cardiology. It provides a structured decision tree to guide clinical decision-making, based on ESC 2019 Dyslipidemia + ESC 2023 ACS Guidelines.

What guideline is the Post-MI Secondary Prevention (ESC 2023) based on?

This algorithm is based on ESC 2019 Dyslipidemia + ESC 2023 ACS Guidelines (DOI: 10.1093/eurheartj/ehz455).

What are the limitations of the Post-MI Secondary Prevention (ESC 2023)?

Known limitations include: Drug dosing not included; Cardiac rehab details simplified; Does not address CABG-specific considerations. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Post-MI Secondary Prevention (ESC 2023) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free